EP1240102A1 - Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse - Google Patents

Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse

Info

Publication number
EP1240102A1
EP1240102A1 EP00967869A EP00967869A EP1240102A1 EP 1240102 A1 EP1240102 A1 EP 1240102A1 EP 00967869 A EP00967869 A EP 00967869A EP 00967869 A EP00967869 A EP 00967869A EP 1240102 A1 EP1240102 A1 EP 1240102A1
Authority
EP
European Patent Office
Prior art keywords
tricalcium phosphate
bone
phosphate
algae
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP00967869A
Other languages
German (de)
English (en)
Other versions
EP1240102B1 (fr
Inventor
Margarita Jordanova-Spassova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1240102A1 publication Critical patent/EP1240102A1/fr
Application granted granted Critical
Publication of EP1240102B1 publication Critical patent/EP1240102B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/16—Oxyacids of phosphorus; Salts thereof
    • C01B25/26—Phosphates
    • C01B25/32—Phosphates of magnesium, calcium, strontium, or barium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Definitions

  • Tricalcium phosphate-containing hydroxyapatite material with a microporous structure Tricalcium phosphate-containing hydroxyapatite material with a microporous structure
  • the invention relates to a tricalcium phosphate-containing hydroxyapatite material, a process for its preparation and the use of the
  • Hydroxyapatite material in the field of bone surgery and as a filter material is Hydroxyapatite material in the field of bone surgery and as a filter material.
  • the bone implant In order to facilitate the growth in the body, the bone implant should have a structure that that of the
  • Bone is as similar as possible.
  • the implant material should also be suitable as a carrier for active substances, such as growth-promoting or inhibiting substances.
  • a hydroxyapatite material which consists of the Calcium carbonate skeleton is obtained from lime-encrusting algae. Such a material is described in DE 37 09 897 C2. To mask the magnesium naturally present in the algae and the formation of (ß-tricalcium phosphate during the production of the
  • the reaction mixture To prevent Hydroxyapatit Mate ⁇ als, there is preferably added Fluo ⁇ d to the reaction mixture.
  • the granular hydroxylapatite material obtained by hydrothermal synthesis with slaked lime as a binder is vibrated into a molded body and then subjected to hydrothermal treatment again.
  • the bone implant thus obtained has a high mterconnective porosity and a high specific surface. In its chemistry and crystalline structure, it is much more similar to bones than other bone replacement materials.
  • hydroxyapatite material Despite the excellent properties of the hydroxyapatite material described in DE 37 09 897 C2, it is desirable to have a bone substitute material available whose absorption in the organism is further improved and which leads to an even faster new bone formation. It has been found that hydroxyapatite material has relatively good biological properties
  • Tricalciumphosphac the organic degradation time of tricalcium phosphate is much shorter. It is desirable to have a biodegradation time that is approximately synchronized with the time with which the bone grows in place of the degraded bone substitute material. This leads to the requirement on the bone substitute material that the breakdown time can be set at least within certain limits during production and thus accelerated bone formation is promoted without the material being broken down too quickly and thus creating an interstice filled with connective tissue, for example.
  • the object of the invention is to provide a bone substitute material which has a high interconnected pore structure, is very well tolerated by the body and has improved and controllable absorption in the organism and thus leads to accelerated new bone formation.
  • the bone substitute material should also be suitable as a carrier for active ingredients such as growth-promoting or inhibiting substances.
  • the problem is solved with the tricalcium phosphate-containing hydroxyapatite material with a microporous structure according to claim 1.
  • the invention further relates to a method for producing this material according to claim 5 and its use in particular in bone surgery and as a filter material according to claim 19. Preferred embodiments and Procedures are set out in the subclaims.
  • Tricalcium phosphate content which is significantly higher than that of a hydroxyapatite material, which was obtained in a conventional manner from calcareous algae.
  • ß-tricalcium phosphate in hydroxylapatite material, which consists of lime encrusted Algae was obtained depends on the amount of magnesium ions that are present in the production of the hydroxyapatite material.
  • naturally occurring algae naturally have a certain magnesium content.
  • This natural content of magnesium in algae is normally around 2.5%, in exceptional cases up to around 6% by weight. This leads to a content of up to 10% by weight, in exceptional cases also up to about 20% by weight, of ⁇ -tricalcium phosphate in a hydroxyapatite material prepared from these algae according to DE 37 09 897 C2.
  • the magnesium is present in the algae in an at least partially m form that is embedded in the structure, namely predominantly in the form of MgC0 3 , MgO and (Ca, Mg) COj, which apparently means that this magnesium is not only ß-Tncalciumphosphat is generated, but also other disturbing phases with magnesium content are generated.
  • MgC0 3 , MgO and (Ca, Mg) COj which apparently means that this magnesium is not only ß-Tncalciumphosphat is generated, but also other disturbing phases with magnesium content are generated.
  • the magnesium naturally present in the algae starting material is masked by the targeted addition of fluorine ions in order to suppress the formation of the calcium phosphate.
  • the invention is based on the knowledge that a hydroxyapatite material with a T ⁇ calciumphosphat content, which is higher than the content that would automatically set when using a certain type of algae as the starting material, with regard to absorption in the organism and the requirement of New bone formation is improved compared to the conventional hydroxyapatite material without the other advantageous properties deteriorating.
  • This increased tricalcium phosphate content is achieved through the targeted addition of magnesium ions during the production of the material.
  • the invention thus relates to a tricalcium phosphate-containing hydroxylapatite material which can be obtained by converting an algae hard tissue freed from organic compounds into an alkaline aqueous solution
  • the tricalcium phosphate content in the end product is preferably between 50 and 90% by weight.
  • magnesium ions in the form of a magnesium salt to the mixture of the solid starting materials (hard algae tissue and phosphate salt).
  • the addition of the magnesium ions must not exceed 15% by weight, since otherwise an excessive amount of other undesirable magnesium-containing phases, such as e.g. ß-Dittmarit (MgNH 4 P0 4 * 6H 2 0).
  • the Mg 2+ contents in the mixture of the solid starting materials should be between 0.75 and 6% by weight.
  • the tricalcium phosphate-containing hydroxylapatite material according to the invention combines all the advantages which are already known from the material described in DE 37 09 897 C2.
  • the hydroxyapatite material according to the invention retains the microporous structure of the algae hard tissue, which was used as the starting material, and thus has a very high interconnectivity porosity. Because of the large porosity, the hydroxyapatite material according to the invention can also be used excellently as a filter material.
  • the specific surface of the material is very high. The material is very well tolerated by the body and chemically similar to bone, making it an excellent bone replacement material.
  • the tricalcium phosphate content and thus the resorptive properties can also be specifically adjusted via the concentration of the magnesium ions. With increasing tricalcium phosphate content, absorption in the body becomes faster. Conversely, a higher hydroxylapatite content slows down absorption.
  • the hydroxyapatite material according to the invention is also exceptionally suitable as a carrier material for active substances such as growth-promoting or inhibiting substances. Specific examples are antibiotics, chemotherapy drugs, anti-tumor compounds and bone-inducing substances. Bone morphogenic proteins (BMP), for example, can be mentioned as bone-inductive substances.
  • the tricalcium phosphate-containing hydroxylapatite material contains at least one active ingredient.
  • This can either be in the hydroxyapatite material according to the invention or in the material produced from it Bone substitute material can be incorporated, or it is present as a coating on a bone substitute material which was produced using the hydroxyapatite material containing tricalcium phosphate according to the invention.
  • the at least one active ingredient is expediently applied or mixed in to the hydroxylapatite material or the bone substitute material in a clinically active amount.
  • any algae hard tissue that has previously been used for the production of hydroxlapatite materials can be used as the algae hard tissue, which is used as the starting material for the hydroxyapatite material according to the invention.
  • Algae hard tissue which was obtained from calcareous seaweed, is particularly suitable.
  • the species Amphiroa Ephedra, Corallinacea or Codiacea can be mentioned as examples of these seaweed.
  • These algae are expediently macerated, for example pyrolyzed at 700 ° C. for about a day and then granulated.
  • the hard algae tissue obtained consists predominantly of calcium carbonate (approx. 95% by weight), the remaining approximately 5% by weight are mainly calcium oxide and magnesium oxide.
  • Algae hard tissue and phosphate salt are selected in a manner known per se so that the ratio of calcium to phosphorus corresponds to the ratio in the hydroxyapatite.
  • the ratio of calcium to phosphorus in the hydroxyapatite is about 1.67.
  • the weight ratio of hard algae to phosphate salt is Usually in the range of 1: 0.8 to 1: 1.5, preferably 1: 0.95 to 1: 1. The weight ratio fluctuates somewhat depending on the calcium content of the hard algae tissue used.
  • the magnesium salt is expediently added in such an amount that the content of tricalcium phosphate in the end product is between 50 and 90% by weight.
  • Magnesium nitrate is used as the preferred source of the magnesium ions. In principle, however, other water-soluble magnesium salts can also be used.
  • diammonium hydrogen phosphate serves as the preferred phosphate compound.
  • the method according to the invention is not restricted to this salt.
  • reaction components mentioned above are reacted in alkaline at elevated temperature.
  • a preferred pH range is between 8 and 11.
  • the reaction is particularly expedient at a pH between 9 and 9.5.
  • all water-soluble bases can be used to adjust the pH.
  • Ammonia is particularly preferred.
  • a suitable temperature range for carrying out the process according to the invention is between 150 and 250 ° C., in particular between 200 and 250 ° C.
  • a particularly preferred temperature range is between 230 and 250 ° C. At this temperature, the reaction will usually take at least 24 hours.
  • the method according to the invention is expediently carried out at elevated pressure. It has proven particularly suitable to carry out the reaction in an autoclave. Preferably, one with an inert coating provided autoclave. An autoclave lined with polytetrafluoroethylene is particularly suitable.
  • the autoclave is expediently filled to a maximum of two thirds so that the saturated steam pressure can be established during the implementation.
  • An algae hard material obtained by macerating algae of the species Corallma officmalis is filled in the form of a granulate with a grain size of more than 0.5 mm.
  • (NH 4 ) 2 HP0 4 is used as the phosphate salt.
  • the weight ratio of hard algae to the phosphate salt is 1: 0.95.
  • the phosphate salt is added in the form of a water solution, the weight ratio of phosphate salt to water being about 1: 4.
  • Magnesium is also added to the autoclave in the form of Mg (N0 3 ) 2 .6H 2 0. The amount is 2.5% by weight of magnesium, based on the solids content in the autoclave.
  • Process steps (a), (b) and (d) correspond to example 1, but the synthesis is carried out in a temperature range from 200 ° C. to 240 ° C.
  • the temperature m of this embodiment varies, the
  • Synthesis first takes place for two hours at a temperature of 200 ° C. Then the temperature is raised to 240 ° C for the next two hours, then reset to 200 ° C. This cycle is again maintained for a total of 24 hours. The change in
  • the change in the sintering temperature changes the thermodynamic conditions in the autoclave during the entire process, so that the crystallization processes take place, but the growth of the crystallites is slowed down and these ultimately remain small. This is a procedure for maintaining the stability of the algae skeleton.
  • the tricalcium phosphate phase has a crystallite size of 100 to 150 rar and the apatite phase a crystallite size of approx. 50 nm.
  • a crystallite size of 30 nm can be used for the apatite phase and 40 to 45 for the tricalcium phosphate phase nm can be reached.
  • the temperature of the hydrothermal synthesis can also be varied between 200 ° C. and 240 ° C. every four hours.
  • the highest concentrations of tricalcium phosphate in the product according to the present invention is approximately 90%, the remainder being mainly hydroxylapatite.
  • the structure is stable and the individual cores of the granulate are hard enough.
  • the maximum amount of Mg added is 5.5 to 6.0% by weight, calculated on the amount of the burned algae (calcite hard tissue).
  • the addition is approx. 0.75% by weight, at a desired concentration of 60% approx. 3.0% by weight. So there is a leap in terms of the addition of Mg, which is necessary to achieve a concentration of tricalcium phosphate of well over 50%. Such a concentration can be achieved with the described, particularly suitable procedure of temperature variation.
  • the excess amount of magnesium required for the reaction is thus given the function of a catalyst which the natural proportion of magnesium in the burned algae does not have in the form of MgC0 3 , MgO and (Ca, Mg) C0 3 integrated in the crystal network.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00967869A 1999-10-18 2000-10-13 Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse Expired - Lifetime EP1240102B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19950113A DE19950113A1 (de) 1999-10-18 1999-10-18 Tricalciumphosphat-haltiges Hydroxylapatit-Material
DE19950113 1999-10-18
PCT/EP2000/010117 WO2001028919A1 (fr) 1999-10-18 2000-10-13 Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse

Publications (2)

Publication Number Publication Date
EP1240102A1 true EP1240102A1 (fr) 2002-09-18
EP1240102B1 EP1240102B1 (fr) 2004-10-27

Family

ID=7926022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00967869A Expired - Lifetime EP1240102B1 (fr) 1999-10-18 2000-10-13 Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse

Country Status (5)

Country Link
EP (1) EP1240102B1 (fr)
AT (1) ATE280736T1 (fr)
AU (1) AU7787500A (fr)
DE (2) DE19950113A1 (fr)
WO (1) WO2001028919A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR152100A0 (en) 2000-11-16 2000-12-14 University Of Technology, Sydney Method for treating coral
DE10113108B4 (de) * 2001-03-15 2007-07-26 Dot Gmbh Wirkstoffhaltige Calciumphosphat-Materialien
KR20020096521A (ko) * 2001-06-20 2002-12-31 홍국선 고강도 생체활성 세라믹복합체 및 그 제조방법
GB0609815D0 (en) * 2006-05-18 2006-06-28 Univ Belfast Process for preparing hydroxylapatite
DK3777904T3 (da) * 2019-08-16 2022-07-04 Univ Heidelberg Osteotrop knogleerstatning
CN112358317A (zh) * 2020-11-20 2021-02-12 佳木斯大学 一种医用骨再生修复纳米生物陶瓷材料及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929971A (en) * 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
JPS59171545A (ja) * 1983-03-18 1984-09-28 株式会社 吉田製作所 リン酸カルシウム複合剤
DE3542744C1 (de) * 1985-12-03 1987-05-27 Ewers Rolf Poroeses Hydroxylapatit-Material
DE3709897A1 (de) * 1987-03-26 1988-10-06 Ewers Rolf Verfahren zur herstellung eines hydroxylapatitmaterials
GB9215356D0 (en) * 1992-07-20 1992-09-02 Univ Reading The Bone materials
US5783217A (en) * 1995-11-07 1998-07-21 Etex Corporation Low temperature calcium phosphate apatite and a method of its manufacture
BG101544A (en) * 1997-05-30 1998-11-30 Медицински Университет-Ректорат Method for the preparation of biologically active coatings over titanium osteal implants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0128919A1 *

Also Published As

Publication number Publication date
DE50008445D1 (de) 2004-12-02
ATE280736T1 (de) 2004-11-15
EP1240102B1 (fr) 2004-10-27
DE19950113A1 (de) 2001-05-03
AU7787500A (en) 2001-04-30
WO2001028919A1 (fr) 2001-04-26

Similar Documents

Publication Publication Date Title
EP0984901B1 (fr) Gel d'hydroxylapatite
DE69702610T2 (de) Verfahren zur herstellung von hydroxylapatit-beschichtungen
DE60318613T2 (de) Apatit/collagen-vernetztes poröses material mit selbstorganisiertem apatit/collagen-verbundstoff und herstellungsverfahren dafür
EP0003979B1 (fr) Dépôt pharmaceutique implantable et méthode pour sa fabrication
DE69909850T2 (de) Mit einem magnesiumsalz stabilisierter hydraulischer brushitzement
DE2724972C2 (fr)
DE3831260C2 (fr)
EP1121161B1 (fr) Composition pour implantation dans le corps d'un homme ou d'un animal
EP1153621A1 (fr) Biociments basés sur le mélange TCP-PHA présentant une résistance améliorée à la compression
DE69804506T2 (de) Verfahren zur herstellung von mit karbonat und magnesium substituiertem hydroxyapatit
DE60201528T2 (de) Herstellungsprozess biofunktioneller hydroxylapatitbeschichtungen und mikrosphären für in-situ wirkstoffverkapselung
DE68928816T2 (de) Kalziumphosphatmineralzusammensetzungen sowie Verfahren zu deren Herstellung
DE68912302T2 (de) Härtendes material für medizinischen und dentalen gebrauch.
DE69228793T2 (de) Verfahren zur herstellung eines mit hydroxylapatit überzogenen implantats
DE69809158T2 (de) Calciumphosphatzement und Calciumphosphatzementzusammensetzung
EP1511521B1 (fr) Preparations de ciment d'apatite de strontium et leurs utilisations
DE3038047A1 (de) Fuellmaterial
CH632158A5 (de) Knochenersatz-, knochenverbund- oder prothesenverankerungswerkstoff.
DE4124898A1 (de) Mit apatit ueberzogene tetracalciumphosphat-teilchen
CH664086A5 (de) Glasfasermaterial.
EP1240102B1 (fr) Hydroxyapatite contenant du phosphate tricalcique, a structure microporeuse
DE3872862T2 (de) Zusammensetzung zur herstellung eines haertbaren calciumphosphatartigen materials und verfahren zur herstellung eines derartigen materials.
DE69005074T2 (de) Biomaterial zur Füllung von Knochen oder Zähnen und Verfahren zu seiner Herstellung.
EP4493529A1 (fr) Engrais granulaire appauvri en métaux lourds et enrichi en phosphate, procédé de production, dispositif et utilisation
EP0237043B1 (fr) Matériau biocompatible en forme de feuille contenant du phosphate de calcium et son procédé de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021029

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT CH DE FR GB LI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041027

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: GERMAN

REF Corresponds to:

Ref document number: 50008445

Country of ref document: DE

Date of ref document: 20041202

Kind code of ref document: P

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20050228

REG Reference to a national code

Ref country code: FR

Ref legal event code: RN

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20041027

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: FC

EN Fr: translation not filed
ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050728

EN Fr: translation not filed
REG Reference to a national code

Ref country code: FR

Ref legal event code: EERR

Free format text: CORRECTION DE BOPI 05/51 - BREVETS EUROPEENS DONT LA TRADUCTION N A PAS ETE REMISE A L INPI. IL Y A LIEU DE SUPPRIMER : LA MENTION DE LA NON REMISE. LA REMISE DE LA TRADUCTION EST A CONSIDERER COMME NULLE ET NON AVENUE.

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE KLEIN & KLEIN

Ref country code: CH

Ref legal event code: PUE

Owner name: ALGIPAT PROJECT HOLDING GMBH

Free format text: JORDANOVA-SPASSOVA, MARGARITA#BL. 3, EING. A, APP. 10, BOUL. "PETKO TODOROV"#1404 SOFIA (BG) -TRANSFER TO- ALGIPAT PROJECT HOLDING GMBH#DOMINIKANERBASTEI 19#1010 WIEN (AT)

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20091014

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20091123

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101013

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20110908 AND 20110914

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

Ref country code: CH

Ref legal event code: PUE

Owner name: LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH

Free format text: ALGIPAT PROJECT HOLDING GMBH#DOMINIKANERBASTEI 19#1010 WIEN (AT) -TRANSFER TO- LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH#MUDERBOLZ 5 1/2#87527 OFTERSCHWANG (DE)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 50008445

Country of ref document: DE

Owner name: LOGON PATENTVERWERTUNGS-VERWALTUNGS GMBH, DE

Free format text: FORMER OWNER: ALGIPAT GMBH, WIEN, AT

Effective date: 20120209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101031

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20151026

Year of fee payment: 16

Ref country code: CH

Payment date: 20151026

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20161102

Year of fee payment: 17

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20161013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161013

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161031

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 50008445

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180501